Skin Therapy Letter

Skin Therapy Letter Home Page DermWebat UBC
Subscription Information
Index • Volume 3 • Part 2 of 2
  • Articles are indexed by drug names, trade-names (marked ®), and disease terms. Bold entries refer to major references.
...Return to Part 1 of 2
Drug name Issue:Page Issue:Page Issue:Page Issue:Page
Kaposi’s sarcoma 1:4      
Keflex® 2:3      
Keloid scars 1:6      
Keratinization 5:2      
Keratinocytes 5:2      
Ketoconazole 4:4      
Ketoconazole shampoo 4:4      
Labial herpes 2:4      
Lactic acid 5:1.2      
Lamisil® 4:4      
Lamivudine 2:6 5:6    
Laser light 1:3      
Laser system 1:6      
Laser resurfacing 2:3,4      
Latex devices 2:5      
Leprosy 5:6      
Leprosy vaccine 5:6      
Levulan® 1:4      
Lichen planus 6:1,2      
Lichenoid drug eruption 6:2      
Lidocaine/Prilocaine 4:6      
Lindane 2:5      
Lipitor® 4:6      
Locoid® 2:6      
Lustra® 5:6      
Lutetium texaphyrin 1:4      
Male pattern hair loss 4:1,2,5 6:6    
Malignant melanoma 4:5      
Mectizan® 2:5      
Melanoma 1:5 6:5    
Malassezia furfur 2:6      
Mentax® 2:6      
Metronidazole 2:6 3:3,4    
Mycobacterium leprae 5:6      
Microsporum canis 4:3,4      
Minocycline (Minocin®) 3:3,4 5:6    
Minoxidil 3:6 4:2,5    
Mupirocin calcium cream 3:6      
Mycosis fungoides 1:4      
Drug name Issue:Page Issue:Page Issue:Page Issue:Page
Nail psoriasis 6:3,4      
Nail ridging 6:3      
Neoral® 1:6 4:5    
New drug treatments 4:5      
Non-melanoma skin cancer 1:4      
Non-steroidal anti-inflammatorie 6:1      
Norgestimate/Ethinyl estradiol 4:6      
Noritate® 2:6      
Ocular rosacea 3:3      
Onchocerciasis 2:5      
Onycholysis 6:4      
Oral hygiene 6:1      
Oral lichen planus 6:1,2      
Oxiconazole nitrate 2:6      
Oxistat® 2:6      
Paresthesia 3:5      
Penciclovir 4:5      
Penicillin 2:3      
Percutan. absorption 2:1      
Peripheral neuropathy 3:5      
Periungual psoriasis 6:3      
PERT 3:4      
Phocomelia 3:1      
Photoaging 5:1,2 6:5    
Photochemotherapy 6:2      
Photodynamic therapy (PDT) # 1:3,4      
Photofrin® 1:3,4      
Photosensitivity 5:2      
Pityriasis versicolor 2:6      
Podophyllin 2:1,2      
Podophyllotoxin 2:1      
Polyhydroxy AHA 5:1      
Pomphylyx 3:2      
Porfimer sodium 1:3,4      
Propecia® 4:1,2,5 6:6    
Proscar® 4:2      
Protease inhibitors 5:6 6:6    
Prurigo nodularis 3:2      
Psoriasis 3:1–6 6:3,6    
Psoriatic onycholysis 6:3      
Psycho-active drugs 2:5      
Psychoses 5:3–5      
Pulsed dye laser 3:3,4      
PUVA 1:3      
Pyoderma gangrenosum 3:2      
Quinolones (4th gen.) 5:6      
Drug name Issue:Page Issue:Page Issue:Page Issue:Page
Recalcitrant rosacea 3:3      
Red laser light :3      
Regranex® 3:6 4:5    
Retin A® micro 4:5      
Rhinophyma 3:3      
Roaccutane® 5:3,4      
Rogaine® 4:2,5      
Rosacea 2:6 3:3,4    
Rosacea conglobata 3:3      
Rosacea fulminans 3:3      
SAER (spont adv. react. reports) 5:3      
Scabies 2:5      
Scars 1:6      
Scleroderma 5:6      
Seborrhea 4:5      
Seborrheic dermatitis 1:1      
Selenium sulphide 4:3,4      
Silicone based device 1:6      
SKAR CARE® 1:6      
Skin cancer 1:3      
Skin Cap® 1:1,2,5,6      
Skin discoloration 5:6      
Skin resurfacing 2:3      
Skin sensitivity 1:3      
Skin substitute 4:5      
Sodium sulfacetamide 3:3,4      
Solarase gel® 1:6 5:6    
Soriatane® 4:5      
Sporonox® 2:6 4    
Squamous cell carcinoma 2:1 6:1    
Staphylococci 2:3      
Staphylococcus aureus 3:6      
Streptococci 2:3      
Streptococcus pyogenes 3:6      
Strongyloidiasis 2:5      
Subungual hyperkeratosis 6:4      
Suicide 5:3,4,5      
Sulphur 3:3      
Sun protection 3:4      
Sunscreen controversies 6:5      
Sunscreens 2:3 5:2 6:5  
Drug name Issue:Page Issue:Page Issue:Page Issue:Page
T cell mediated immune response 6:1      
Tazarotene (Tazorac®) 4:5      
Telangiectasia 3:3      
Terbinafine 2:6      
Testosterone 4:2      
Tetracycline 3:3,4      
Thalomid® 3:1,2,5      
Thalidomide 3:1,2,5      
Tinea capitis 4:3,4      
Tinea cruris 2:6      
Tinea pedis 2:6 3:6    
Tinea tonsurans 4:4      
Tinea versicolor 2:6      
Tissue adhesive 4:6      
Topical corticosteroids 6:2      
Topical retinoids 6:2      
Tretinoin 2:3 3:3 5:1,2  
Tretinoin gel 4:6      
Triamcinolone acetonide 6:3      
Trichloroacetic acid 2:1      
Trichophyton mentagroph. 2:6      
Trichophyton rubrum 2:6      
Trichophyton violaceum 4:3      
Trichophyton 4:3      
Tri-Cyclen® 4:6      
Trigger factors 3:3      
Trovafloxacin 5:6      
Trovan® 5:6      
Tumor necrosis factor alpha 2:1      
UV induced discoloration 5:6      
UVA/UVB penetration 6:5      
Vaccine–leprosy 5:6      
Valaciclovir 2:4,6 4:5    
Valtrex® 2:4,6 4:5    
Vectavir® 4:5      
Venous leg ulcers 3:6      
Viral infections 2:4      
Virulizin® 4:5      
Vitamin D deficiency 6:5      
Warts 2:6      
Wound healing 4:5      
Zidovudine 2:6 5:6    
Zinc pyrithione 1:1,5,6      
Zoophilic fungus 4:4      
Zovirax® 6:6      
EDITOR: Stuart Maddin ASSOCIATE EDITOR: David I. McLean INTERNET EDITOR: Harvey Lui PRINCIPAL MEDICAL WRITER: Rodger Hall MANUSCRIPT EDITOR: Rodger Hall  EDITORIAL ADVISORY BOARD: Kenneth A. Arndt, Beth Israel Hospital & Harvard Medical School, Boston; Wilma Fowler Bergfeld, Cleveland Clinic, Cleveland; Jan D. Bos, University of Amsterdam, Amsterdam; Enno Christophers, Universitäts-Hautklinik, Kiel; Hugo Degreef, Catholic University, Leuven; Richard L. Dobson, Medical University of South Carolina, Charleston; Boni E. Elewski, Case Western Reserve University, Cleveland; Barbara A. Gilchrest, Boston University School of Medicine, Boston; W. Andrew D. Griffiths, St. Johns Institute of Dermatology, London; Vincent C.Y. Ho, University of British Columbia, Vancouver; James J. Leyden, University of Pennsylvania, Philadelphia; Howard I. Maibach, University of California Hospital, San Francisco; Larry E. Millikan, Tulane University Medical Center, Louisiana; Takeji Nishikawa, Keio University School of Medicine, Tokyo; Constantin E. Orfanos, Freie Universitäts Berlin, Universitätsklinikum Benjamin Franklin, Berlin; Stephen L. Sacks, Viridae Clinic Sciences, Vancouver; Alan R. Shalita, SUNY Health Sciences Center, Brooklyn; Stephen K. Tyring, University of Texas Medical Branch, Galveston; John Voorhees, University of Michigan, Ann Arbor; Klaus Wolff, University of Vienna, Vienna
Skin Therapy Letter®. (ISSN 1201-5989) Copyright 1998 by International Skin Therapy Newsletter Inc. All rights reserved. Reproduction in whole or in part by any process in whole or in part is strictly forbidden without prior consent of the publisher in writing.
Published six times yearly by International Skin Therapy Newsletter Inc., 835 West Tenth Avenue, Vancouver, British Columbia, Canada V5Z 4E8. Tel: (604) 874-6112. Fax: (604) 873-9919. Annual subscription: Canadian $85 individual; $155 institutional (GST included). US $60 individual; $110 institutional. Outside North America: US$80 individual; $130 institutional. Quotes on multiple subscriptions and student rates supplied upon request.
Skin Therapy Letter Editor: Dr. Stuart Maddin Index to Volume 3
Return to Top